Suven Pharma reported a 78% YoY rise in Q3FY25 net profit to Rs 83.3 crore, with revenue growing 40% to Rs 307.2 crore, driven by its CDMO ...

After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...

Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...

Promoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...

Private equity firm Advent International has completed its majority acquisition of Indian contract development and manufacturing organisati...

According to the latest shareholding pattern available with the exchanges, as of 30 June 2023, 60% of the company's shareholding is with th...

Post the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...

The issue will ensure one rights equity share for every two fully-paid up equity shares held by the eligible shareholders of the company as...

The company informed exchanges that the board of directors will meet on June 24, 2022, to consider raising of funds through the issue of sh...

Suven Pharma’s total revenues grew 40% YoY to Rs.364 crore with the Formulations and CRAMS (pharma) reporting stellar growth this quarter o...

Shares of Suven Life have soared about 25 per cent in the last one month. In the last one year, the company has delivered over 65 per cent ...

The brokerage says despite a significant run up, there is still scope for upside as the company is still trading at a significant discount ...

Buy Suven Life Sciences Ltd. at a price target of Rs 312.0 and a stoploss at Rs 280 from entry point.

Buy Suven Life Sciences at a price target of Rs 250 and a stop loss at Rs 202 from entry point.

Buy Suven Life Sciences at a price target of Rs 205 and a stop loss at Rs 166 from entry point.

Typically, it is a pharma stock which enjoys very high margins. In addition, it has a huge monetisation opportunity for one of its molecule...

In a BSE filing, Suven Life Sciences said, "It has concluded its Rs 200 crore fund raising exercise through the Qualified Institutional Pla...